Who
Sandra Beaver
Director
Company insider
Files Form 4 as: Director, Tandem Diabetes Care; Chief Financial Officer, Evolus.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $438K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 5 Sep 2022
- Last trade
- 20 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 May 2026filed 22 May 2026 | TNDM Tandem Diabetes Careoption or derivative · Medical Devices | SEC FORM 4 Code A | —5,110 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | TNDM Tandem Diabetes Careoption or derivative · Medical Devices | SEC FORM 4 Code A | —5,110 at $0.00 | filing |
| 7 Nov 2025filed 25 Nov 2025 | TNDM Tandem Diabetes Careoption or derivative · Medical Devices | SEC FORM 4 Code A | —20,242 at $0.00 | filing |
| 13 May 2025filed 14 May 2025 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $65K6,494 at $10.02 | filing |
| 18 Mar 2025filed 20 Mar 2025 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $119K8,996 at $13.26 | filing |
| 7 Mar 2025filed 11 Mar 2025 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,663 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,813 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —35,663 at $0.00 | filing |
| 23 Dec 2024filed 26 Dec 2024 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $17K1,586 at $10.85 | filing |
| 6 Sep 2024filed 6 Sep 2024 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $49K3,276 at $14.98 | filing |
| 10 May 2024filed 14 May 2024 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $31K2,423 at $12.72 | filing |
| 19 Mar 2024filed 21 Mar 2024 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $79K5,672 at $13.92 | filing |
| 22 Feb 2024filed 23 Feb 2024 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $24K1,821 at $13.08 | filing |
| 21 Feb 2024filed 23 Feb 2024 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —13,115 at $0.00 | filing |
| 7 Feb 2024filed 9 Feb 2024 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,606 at $0.00 | filing |
| 7 Feb 2024filed 9 Feb 2024 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,337 at $0.00 | filing |
| 7 Feb 2024filed 9 Feb 2024 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —35,211 at $0.00 | filing |
| 6 Sep 2023filed 8 Sep 2023 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $31K3,178 at $9.70 | filing |
| 16 Aug 2023filed 16 Aug 2023 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $23K2,211 at $10.27 | filing |
| 14 Aug 2023filed 16 Aug 2023 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —19,672 at $0.00 | filing |
News
Lifecore Biomedical (NASDAQ:LFCR) vs. Evolus (NASDAQ:EOLS) Head to Head ComparisonEOLS · themarketsdaily.com · 14 Oct 2026Evolus (NASDAQ:EOLS) & Talphera (NASDAQ:TLPH) Financial ComparisonEOLS · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Sandra Beaver; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.